Is Aligos Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Aligos Therapeutics Inc (ALGS) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Aligos Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Aligos Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Aligos Therapeutics Inc?

Muslim investors may consider investing in Aligos Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Aligos Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Aligos Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Aligos Therapeutics Inc updated?

The Shariah compliance status of Aligos Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Aligos Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Aligos Therapeutics Inc?

You can check the latest Shariah compliance status of Aligos Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ALGS Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 10, 2026

Report Source: 2025 Annual Report

Aligos Therapeutics Inc. Stock Analysis ALGS

United States Health Care Nano Cap Report: 2025 Annual

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 82 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Key Statistics of Aligos Therapeutics Inc (ALGS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$5.68$6.66

Today's Open

$6.49

Volume

179.28K

P/E Ratio (TTM)

52 Week Range

$5.12$13.69

Market Cap

39.29M

Avg. Volume

435.40K

Dividend Yield

Financial Metrics & Statements of Aligos Therapeutics Inc (ALGS)

FAQ's for Aligos Therapeutics Inc (ALGS)

According to Musaffa’s Shariah screening methodology, Aligos Therapeutics Inc (ALGS) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.